| Dr Michael Purvin, MD | |
|
3901 Rainbow Blvd, Kansas City, KS 66160-8500 | |
| (013) 588-5000 | |
| Not Available |
| Full Name | Dr Michael Purvin |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 14 Years |
| Location | 3901 Rainbow Blvd, Kansas City, Kansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215235692 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 04-38427 (Kansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Kansas Hospital | Kansas city, KS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kansas University Physicians, Inc. | 8921911587 | 1456 |
News Archive
Two Washington University in St. Louis scientists are imitating nature as they attempt to solve one of the most difficult problems in orthopedic surgery: reattaching tendon to bone.
In a study published on Wednesday in the Lancet, researchers from the Centers for Disease Control and Prevention found that "[a]mong 1,278 patients who were resistant to two or more first-line tuberculosis drugs in Estonia, Latvia, Peru, Philippines, Russia, South Africa, South Korea and Thailand, 43.7 percent showed resistance to at least one second-line drug," which "suggest[s] the deadly disease may become 'virtually untreatable,'" according to the study, Bloomberg Businessweek reports.
A three-year project called CAMbrella will receive nearly 1.5 million euros of European Union funding to establish a research network for the study of complementary medicine. The Center for Naturopathic Research at "Rechts der Isar," the university hospital of the Technische Universitaet Muenchen will coordinate the project for the winning applicant group, which includes 16 scientific organizations from 12 European countries.
MET protein levels correlate strongly with epithelial-mesenchymal transition phenotype, a treatment-resistant type of colorectal cancer and may be used as a surrogate biomarker, according to new research from The University of Texas MD Anderson Cancer Center.
Juniper Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development of therapeutics for women's health, announced today the first patient has been enrolled in a Phase II clinical trial of COL-1077, a 10% lidocaine bioadhesive gel that is intended as an acute-use anesthetic during minimally invasive gynecologic procedures.
› Verified 7 days ago
| Entity Name | Kansas University Physicians, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003858333 PECOS PAC ID: 8921911587 Enrollment ID: O20040401000328 |
News Archive
Two Washington University in St. Louis scientists are imitating nature as they attempt to solve one of the most difficult problems in orthopedic surgery: reattaching tendon to bone.
In a study published on Wednesday in the Lancet, researchers from the Centers for Disease Control and Prevention found that "[a]mong 1,278 patients who were resistant to two or more first-line tuberculosis drugs in Estonia, Latvia, Peru, Philippines, Russia, South Africa, South Korea and Thailand, 43.7 percent showed resistance to at least one second-line drug," which "suggest[s] the deadly disease may become 'virtually untreatable,'" according to the study, Bloomberg Businessweek reports.
A three-year project called CAMbrella will receive nearly 1.5 million euros of European Union funding to establish a research network for the study of complementary medicine. The Center for Naturopathic Research at "Rechts der Isar," the university hospital of the Technische Universitaet Muenchen will coordinate the project for the winning applicant group, which includes 16 scientific organizations from 12 European countries.
MET protein levels correlate strongly with epithelial-mesenchymal transition phenotype, a treatment-resistant type of colorectal cancer and may be used as a surrogate biomarker, according to new research from The University of Texas MD Anderson Cancer Center.
Juniper Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development of therapeutics for women's health, announced today the first patient has been enrolled in a Phase II clinical trial of COL-1077, a 10% lidocaine bioadhesive gel that is intended as an acute-use anesthetic during minimally invasive gynecologic procedures.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael Purvin, MD 3901 Rainbow Blvd, Kansas City, KS 66160-8500 Ph: (913) 588-5000 | Dr Michael Purvin, MD 3901 Rainbow Blvd, Kansas City, KS 66160-8500 Ph: (013) 588-5000 |
News Archive
Two Washington University in St. Louis scientists are imitating nature as they attempt to solve one of the most difficult problems in orthopedic surgery: reattaching tendon to bone.
In a study published on Wednesday in the Lancet, researchers from the Centers for Disease Control and Prevention found that "[a]mong 1,278 patients who were resistant to two or more first-line tuberculosis drugs in Estonia, Latvia, Peru, Philippines, Russia, South Africa, South Korea and Thailand, 43.7 percent showed resistance to at least one second-line drug," which "suggest[s] the deadly disease may become 'virtually untreatable,'" according to the study, Bloomberg Businessweek reports.
A three-year project called CAMbrella will receive nearly 1.5 million euros of European Union funding to establish a research network for the study of complementary medicine. The Center for Naturopathic Research at "Rechts der Isar," the university hospital of the Technische Universitaet Muenchen will coordinate the project for the winning applicant group, which includes 16 scientific organizations from 12 European countries.
MET protein levels correlate strongly with epithelial-mesenchymal transition phenotype, a treatment-resistant type of colorectal cancer and may be used as a surrogate biomarker, according to new research from The University of Texas MD Anderson Cancer Center.
Juniper Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development of therapeutics for women's health, announced today the first patient has been enrolled in a Phase II clinical trial of COL-1077, a 10% lidocaine bioadhesive gel that is intended as an acute-use anesthetic during minimally invasive gynecologic procedures.
› Verified 7 days ago
Lyna Rehan, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 3901 Rainbow Blvd # Ms 1034, Kansas City, KS 66160 Phone: 913-588-3304 Fax: 913-588-3365 | |
Dr. Joel Kent Grigsby, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3901 Rainbow Blvd, Kansas City, KS 66160 Phone: 913-588-3315 | |
O. Layton Alldredge Jr., MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: Kansas University Medical Ctr, 3901 Rainbow Blvd Ms 1034, Kansas City, KS 66160 Phone: 913-588-3304 | |
Timothy Sowder, Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: Kumc 3901 Rainbow Blvd Ms 1034, Kansas City, KS 66160 Phone: 913-588-3302 Fax: 913-588-3365 | |
Robert P Devine, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 3901 Rainbow Blvd, Kansas City, KS 66160 Phone: 913-588-3315 | |
Jennifer B Kenny, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3901 Rainbow Blvd, Mail Stop 1034, Kansas City, KS 66160 Phone: 913-588-3315 Fax: 913-588-3365 | |
Dr. Sarafina Kristine Kankam, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3901 Rainbow Blvd, Kansas City, KS 66160 Phone: 913-588-5000 |